Download as doc, pdf, or txt
Download as doc, pdf, or txt
You are on page 1of 2

Zoladex (Goserelin Acetate)

in Prostate Cancer Patients


Luteinizing hormone releasing hormone analogue (LHRHa)

AKA gonadotropin releasing hormone super agonist

oIndirectly stimulates an initial release of testosterone in males and estrogen in females


by activating receptors in the pituitary gland

oParadoxically, this leads to a decrease in these hormones due to the feedback loop

Indications

oProstate cancer, metastatic (palliative treatment)

in addition to palliative radiation

oProstate cancer, advanced non-metastatic (Stage B2, Stage C) treatment with an


antiandrogen

in addition to radiation therapy

oBreast cancer, advanced palliation

oEndometriosis

Contraindications

oPregnancy

oHypersensitivity

Adverse Reactions

Dosage

Administration

References
Lexi-Comp Drug Information Handbook. 18th Edition 2009-2010.
Montgomery BSI, Borwell JP, Higgins DM. Does needle size matter? Patient experience of luteinising
hormone-releasing hormone analogue injection. Prostate Cancer and Prostatic Diseases (2005) 8, 66–68.
Thomson Clinical Xpert (Micromedex) [computer program]. Thomson Reuters 2010.
Zoladex LA, Product Monograph. AstraZeneca 2009.
http://www.astrazeneca.ca/documents/ProductPortfolio/ZOLADEX%20LA_PM_en.pdf. Accessed June
2010.

You might also like